<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="pmc-domain-id">2863</journal-id><journal-id journal-id-type="pmc-domain">fcvm</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10175606</article-id><article-id pub-id-type="pmcid-ver">PMC10175606.1</article-id><article-id pub-id-type="pmcaid">10175606</article-id><article-id pub-id-type="pmcaiid">10175606</article-id><article-id pub-id-type="pmid">37187787</article-id><article-id pub-id-type="doi">10.3389/fcvm.2023.1154708</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>A modern day perspective on smoking in peripheral artery disease</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Behrooz</surname><given-names initials="L">Leili</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2189298/overview"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Abumoawad</surname><given-names initials="A">Abdelrhman</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rizvi</surname><given-names initials="SHM">Syed Husain M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1559364/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hamburg</surname><given-names initials="NM">Naomi M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><addr-line>Whitaker Cardiovascular Institute, Boston University Chobanian and Avedisian School of Medicine, Section of Vascular Biology</addr-line>, <institution>Boston Medical Center</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Evans Department of Medicine and Whitaker Cardiovascular Institute</addr-line>, <institution>Boston University Chobanian &amp; Avedisian School of Medicine</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Mahdi Garelnabi, University of Massachusetts Lowell, United States</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Linda Neff, Centers for Disease Control and Prevention (CDC), United States Achuthan Raghavamenon, Amala Cancer Research Centre, India Sainath Babu, MED Institute, United States</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Naomi M. Hamburg <email>nhamburg@bu.edu</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#8224;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">427754</issue-id><elocation-id>1154708</elocation-id><history><date date-type="received"><day>31</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>05</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-16 16:25:31.443"><day>16</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Behrooz, Abumoawad, Rizvi and Hamburg.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Behrooz, Abumoawad, Rizvi and Hamburg</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fcvm-10-1154708.pdf"/><abstract><p>Peripheral artery disease (PAD) is associated with increased risk of cardiovascular morbidity and mortality, poor functional status, and lower quality of life. Cigarette smoking is a major preventable risk factor for PAD and is strongly associated with a higher risk of disease progression, worse post-procedural outcomes, and increased healthcare utilization. The arterial narrowing due to atherosclerotic lesions in PAD leads to decreased perfusion to the limbs and can ultimately cause arterial obstruction and limb ischemia. Endothelial cell dysfunction, oxidative stress, inflammation, and arterial stiffness are among the key events during the development of atherogenesis. In this review, we discuss the benefits of smoking cessation among patients with PAD and the use of smoking cessation methods including pharmacological treatment. Given that smoking cessation interventions remain underutilized, we highlight the importance of incorporating smoking cessation treatments as part of the medical management of patients with PAD. Regulatory approaches to reduce the uptake of tobacco product use and support smoking cessation have the potential to reduce the burden of PAD.</p></abstract><kwd-group><kwd>smoking</kwd><kwd>peripheral artery disease (PAD)</kwd><kwd>atherosclerosis</kwd><kwd>smoking cessation</kwd><kwd>nicotine replacement therapy</kwd><kwd>mechanism of injury</kwd></kwd-group><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="67"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Atherosclerosis and Vascular Medicine</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1.</label><title>Introduction</title><p>Peripheral artery disease (PAD) is a major cardiovascular disease that affects more than 200 million people worldwide and an estimated 8.5 million people in the U.S (<xref rid="B1" ref-type="bibr">1</xref>&#8211;3). It is well known that patients with PAD have a higher risk of mortality and major cardiovascular events (<xref rid="B4" ref-type="bibr">4</xref>). Also, PAD is associated with the lowest quality of life among all symptomatic CVDs (<xref rid="B5" ref-type="bibr">5</xref>). Smoking is a modifiable risk factor for PAD, carrying a three to four-fold increased risk for the development of PAD (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p><p>Smoking contributes to the clinical expression of PAD and smoking cessation has clear clinical benefits. Novel tobacco products including electronic cigarettes (e-cigarettes) raise important questions about their value in reducing the harms of smoking compared to their risk of increasing smoking prevalence. Regulatory strategies that reduce tobacco use and enhance access to smoking cessation treatments have the potential to reduce the PAD burden. The current review focuses on the intersection of smoking with PAD and modern strategies to promote a tobacco-free future.</p></sec><sec id="s2"><label>2.</label><title>The burden of smoking and PAD</title><p>Although the population of adult smokers in the U.S. has declined, 12.5% of adults in the U.S. still smoke (<xref rid="B7" ref-type="bibr">7</xref>). Overall, the burden of smoking-related PAD deaths has declined modestly in both men and women over the past three decades due to the intense regulatory and public education efforts. Yet, in 2019, nearly a quarter of PAD-related deaths remain attributable to tobacco use globally (<xref rid="B8" ref-type="bibr">8</xref>). Secondhand smoke exposure confirmed by urinary cotinine levels has also been linked to clinical PAD (<xref rid="B9" ref-type="bibr">9</xref>). The Global Reduction of Atherothrombosis for Continued Health (REACH) Registry reported that 22% of patients with clinical PAD are current smokers, a prevalence that is double that of patients with other forms of atherosclerotic disease (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Although, PAD is three times more likely to develop in black patients compared to non-Hispanic white patients, prior studies have provided limited information about the association of smoking and incident PAD by race (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>). The Jackson Heart Study assessed the effect of smoking on Black patients with PAD and reported that smoking was associated with 2.2 times the probability of subclinical PAD measured by ankle-brachial index (ABI). Also, Black patients who were smoking more than &gt;20 cigarettes per day and those with higher pack/year had significantly higher odds of subclinical PAD compared to those who were smoking &lt;20 cigarettes per day confirming the importance of smoking intensity (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Active tobacco use in patients with PAD is strongly associated with a higher risk of disease progression, worse post-procedural outcomes, early failure of revascularization therapies, increased hospitalizations, and cardiovascular events including myocardial infarction and death (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Among patients with PAD who have undergone lower extremity revascularization, those who smoke more than one pack a day have a higher risk of major adverse limb events as well as amputation incidence at 1-year follow-up compared to those who smoked less. Patients who were current smokers had a higher mortality rate as well as a lower survival rate without amputation compared to patients who had quit smoking (<xref rid="B13" ref-type="bibr">13</xref>). Patients with PAD have poor functional status and quality of life. The PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) trial reported that older age, female sex, poor access to care, and economic burden were among the risk factors associated with worse outcomes in patients with PAD (<xref rid="B14" ref-type="bibr">14</xref>). Current smokers had evidence of lower ABI and more proximal disease despite being younger.</p></sec><sec id="s3"><label>3.</label><title>Mechanisms of vascular injury due to smoking</title><p>Patients with PAD have disrupted blood flow to the limbs due to the formation of atherosclerotic plaque and the development of atherothrombosis. Cigarette smoking is a well-known contributor to the development of atherosclerosis and PAD (<xref rid="F1" ref-type="fig">Figure&#160;1</xref>). The interaction of genetic predisposition, harmful compounds released in cigarette smoke, metabolism of toxins, and intersection with concomitant risk factors influence the individual PAD expression (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Even a low intensity of ongoing smoking increases cardiovascular risk suggesting that low-intensity toxin exposure not just cumulative lifetime exposure contributes to vascular disease.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Impact of tobacco products on Peripheral Artery Disease (PAD). Combustible cigarettes release multiple potentially harmful constituents into tobacco smoke that induce endothelial injury, promote thrombosis, and accelerate atherothrombosis. Together the toxins in tobacco smoke adversely influence the peripheral vasculature leading to heightened PAD incidence and worse outcomes with established PAD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1154708-g001.jpg"/></fig><p>The pathophysiology of PAD is complex and multifactorial and involves a variety of cells including endothelial cells, inflammatory cells, vascular smooth muscle cells, and platelets (<xref rid="B17" ref-type="bibr">17</xref>). There is evidence from preclinical models linking multiple components of cigarette smoke to the process of injury in all these cell types. Cigarette smoke exposure causes oxidative stress and endothelial cell dysfunction reducing nitric oxide (NO) bioavailability which aggregates endothelial leukocyte interaction, induces the production of inflammatory and proatherogenic cytokines, impairs smooth muscle cell function, and amplifies platelet activation which leads to atherothrombosis (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B18" ref-type="bibr">18</xref>).</p><p>Multiple components of cigarette smoke are potentially harmful compounds. There are many chemicals produced in cigarette smoke that might be responsible for vascular injury. Nicotine is one of the chemicals in cigarette smoke among more than 7,000 different chemicals (<xref rid="B19" ref-type="bibr">19</xref>&#8211;<xref rid="B21" ref-type="bibr">21</xref>). Though nicotine replacement therapy (NRT) is generally safe, there is evidence that links nicotine to adverse cardiovascular effects (<xref rid="B22" ref-type="bibr">22</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>). Nicotine causes vasoconstriction through multiple mechanisms such as stimulating the endothelial cells' alpha-adrenergic receptors by catecholamines and reducing the availability of NO in the endothelial cells (<xref rid="B25" ref-type="bibr">25</xref>). Nicotine inhibits GTP cyclohydrolase 1 (GTPCH1), the key enzyme in B tetrahydrobiopterin (BH4) synthesis. BH4 is necessary for the endothelial NO synthase (eNOS) to produce NO. Thus, in theabsence of BH4, eNOS synthesizes superoxide instead of NO (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Nicotine has been shown to promote atherogenesis in animal models and contribute to the acute cardiovascular effects of e-cigarettes (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Thus, it will be important to investigate the impact of reduced nicotine tobacco products and consider reducing nicotine content in all tobacco products.</p><p>There are additional harmful compounds that are important in the process of atherosclerosis and the development of PAD. Cigarette smoke includes volatile organic compounds (VOCs) such as aldehydes, which are classified as saturated aldehydes including formaldehyde and acetaldehyde, and unsaturated aldehydes acrolein and crotonaldehyde. Acrolein for example can accelerate atherosclerosis through elevated levels of oxidative stress and platelet activation and suppression of circulating angiogenic cell levels (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>).</p><p>E-cigarettes are devices that heat a liquid comprised of propylene glycol, glycerin, and typically nicotine and flavors to form an aerosol. The aerosol contains fewer toxins than tobacco smoke but has substantial levels of VOCs. Ogunwale et al. demonstrated that some aldehydes such as acrolein, formaldehyde, and acetaldehyde are also present in e-cigarette aerosols (<xref rid="B32" ref-type="bibr">32</xref>). E-cigarette use can instigate oxidative stress and inflammation leading to endothelial dysfunction, a major contributor to atherosclerosis. It has been shown that acute use of e-cigarettes induces vascular dysfunction similar to tobacco smoking (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>). Mohammadi et al. demonstrated that both e-cigarette users and cigarette smokers had lower flow-mediated dilation, reduced vascular endothelial growth factor, and NO secretion compared to non-users (<xref rid="B36" ref-type="bibr">36</xref>). Studies have evaluated the effect of e-cigarettes on endothelial cell function by examining freshly isolated venous endothelial cells of e-cigarette users. They reported that e-cigarettes were associated with impaired eNOS activation and endothelial cell dysfunction. While some studies have related the association of e-cigarettes and endothelial cell dysfunction to nicotine, other studies have reported that e-cigarettes induce endothelial cell dysfunction independent of nicotine (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>). It is important to note that Flavoring compounds were also found injurious to endothelial cells and they continue to be included in the majority of e-liquids (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Thus, e-cigarette aerosol has the potential to induce adverse cardiovascular outcomes, though the relative impact of e-cigarette use compared to cigarette smoking on clinical events remains poorly understood.</p></sec><sec id="s4"><label>4.</label><title>Benefits of smoking cessation in PAD</title><p>Four out of every five patients with PAD are either current or former smokers (<xref rid="B41" ref-type="bibr">41</xref>). According to the REACH registry, 22% of patients with clinically evident PAD continue to use tobacco products (<xref rid="B6" ref-type="bibr">6</xref>). There is a rapid decline in cardiovascular risk and major adverse cardiovascular events within a few years after smoking cessation (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Similarly patients with PAD have better outcomes with smoking cessation across multiple clinical dimensions (<xref rid="F2" ref-type="fig">Figure&#160;2</xref>).</p><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Benefits of smoking cessation on clinical outcomes in patients with PAD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1154708-g002.jpg"/></fig><sec id="s4a"><label>4.1.</label><title>Claudication and walking distance</title><p>Smoking is a known independent risk factor for claudication (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Hughson et al. demonstrated that male and female smokers are more likely to develop intermittent claudication by fifteen and seven times more compared with non-smoker males and females, respectively (<xref rid="B44" ref-type="bibr">44</xref>). Smoking cessation has the potential to improve intermittent claudication. In a study by Quick et al. looking into ankle pressures, intermittent claudication, and exercise tolerance, the cohort of patients with PAD who continued to smoke showed a significant decrease in ankle pressures and had no change in their maximum treadmill walking distance. However, the cohort that quit smoking showed significant improvement in the maximum treadmill walking distance over a mean period of 10 months (<xref rid="B45" ref-type="bibr">45</xref>).</p></sec><sec id="s4b"><label>4.2.</label><title>Graft failure and patency</title><p>Multiple studies have shown the negative impact of smoking on the patency of bypass grafts for PAD (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>). A meta-analysis of 29 studies looking at the relationship between smoking and the patency of lower extremity bypass grafts, reported that smoking after lower limb bypass surgery results in a threefold increased risk of graft failure and a number needed to harm of only four. A clear dose-response relationship was present, with decreased patency in heavy smokers compared with moderate smokers. It was also reported that smoking cessation restored patency rates towards the never-smokers group (<xref rid="B46" ref-type="bibr">46</xref>).</p></sec><sec id="s4c"><label>4.3.</label><title>Mortality and amputation-free survival</title><p>The mortality rate among patients with PAD and critical limb ischemia (CLI) is higher compared to the general population. One of every three patients enrolled in the Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI) trial died within three years (<xref rid="B48" ref-type="bibr">48</xref>). Armstrong et al. examined the association of smoking cessation with mortality and amputation-free survival. Among a retrospective cohort of 739 patients with claudication or CLI using the PAD-University of California, Davis Registry; mortality was lower in the successful smoking quitters cohort compared with the continued smokers cohort (14% vs. 31% at five years). The mortality benefit was more evident in the cohort of patients with CLI (18% vs. 43%, respectively) (<xref rid="B49" ref-type="bibr">49</xref>). Also, improved amputation-free survival was noted in the successful smoking quitters cohort compared with the continued smoker cohort with a hazard ratio of 0.43 (95% CI, 0.22&#8211;0.86). A recent study by Reitz et al. assessed 14,350 patients with intermittent claudication who underwent revascularization between 2011 and 2019, from the Veterans Affairs Surgical Quality Improvement Program. They reported that the 30-day mortality was higher (0.6% vs. 0.1%) among the smoker cohort regardless of the procedure modality: endovascular, open, or hybrid revascularization. Also, graft failure was higher across the smoker cohort (2.2% vs. 0.7%) (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>).</p></sec></sec><sec id="s5"><label>5.</label><title>Economic burden of smoking on PAD</title><p>Despite the decline in smoking rates, healthcare costs related to tobacco use are staggering (<xref rid="B52" ref-type="bibr">52</xref>). Analysis of data from the REACH registry estimated the total cost of vascular-related hospitalizations was $21 billion in the U.S. in 2004, with most costs associated with revascularization procedures (<xref rid="B53" ref-type="bibr">53</xref>). A retrospective, cross-sectional study using data from 22,202 patients with PAD, found that hospitalization rates were higher for smokers compared to non-smokers. Smokers had significantly higher rates of more than one hospitalization within a 1-year period compared to non-smokers (49% vs. 36.4%, respectively). The primary hospitalization diagnosis for smokers was significantly more likely related to atherosclerotic disease compared to non-smokers. Smoking was associated with a 35% higher annual hospitalization rate and $18,000 higher annual cost per patient in patients with PAD who smoked (<xref rid="B12" ref-type="bibr">12</xref>). High healthcare costs in addition to worse clinical outcomes associated with patients with PAD who smoke highlight the importance of effective measures for smoking cessation to halt the progression of the disease and reduce the economic burden of PAD.</p></sec><sec id="s6"><label>6.</label><title>Underutilization of smoking cessation treatment</title><p>The American Heart Association/American College of Cardiology 2016 guidelines for the management of patients with PAD who smoke recommend using pharmacotherapy and/or referral to a smoking cessation program (<xref rid="B54" ref-type="bibr">54</xref>). Data from the national health interview surveys reported that 68% of adult smokers wanted to quit and more than half of adult cigarette smokers (55%) have made a quit attempt but only 7.5% ofsmokers were successful (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>). A randomized clinical trial reported that patients with PAD with active smoking who received the intensive intervention (physician advice, smoking cessation counseling, and pharmacologic treatment) had 21.3% rate of 6-month abstinence as compared to 6.8% in the less intensive treatment group who only received verbal advice to quit smoking (<xref rid="B57" ref-type="bibr">57</xref>). Despite the evidence on the efficacy of these interventions, a relatively low number of patients with PAD who are smokers are referred for smoking cessation counseling or pharmacologic treatment (<xref rid="B4" ref-type="bibr">4</xref>). Kalbaugh et al. reported that smokers with PAD were only offered smoking cessation counseling or pharmacologic treatment in about one-third of visits (<xref rid="B58" ref-type="bibr">58</xref>). An analysis from the PORTRAIT registry by Patel et al. assessed the smoking rate and the smoking cessation interventions offered to patients with PAD who presented with new or worsening PAD symptoms and examined the changes in smoking behavior at 1-year follow-up. The predominant strategy used by providers for smoking cessation was to tell them to stop. Out of 474 patients with PAD who were active smokers, less than one in five were referred to a smoking cessation counseling program and only one in ten had received pharmacologic treatment. Among patients who quit smoking, more than a third relapsed which highlights the challenge of continuous abstinence from smoking for patients (<xref rid="B4" ref-type="bibr">4</xref>).</p><p>Incorporating smoking cessation interventions into the vascular clinical workflow has the potential efficacy for higher rates of smoking cessation. The Vascular Physician Offer and Report (VAPOR) trial assessed the feasibility and efficacy of standardized smoking cessation intervention for patients with PAD who were current smokers offered by vascular surgeons (<xref rid="B59" ref-type="bibr">59</xref>). Patients were randomized to either receive the &#8220;offer and report&#8221; smoking cessation intervention vs. usual care. The intervention included: (1) physician-delivered advice for smoking cessation, (2) NRT prescription, and (3) active referral for telephone-based smoking cessation. They reported that delivering smoking cessation intervention including NRT by vascular clinicians is feasible.</p></sec><sec id="s7"><label>7.</label><title>Modalities to support smoking cessation</title><p>There are multiple approved methods that are used for smoking cessation which can either be used alone or in combination including pharmacologic therapy and behavioral approaches with smoking cessation counseling programs. E-cigarettes have been proposed as an aid for smoking cessation but there is a need for more information on their efficacy and safety (<xref rid="F3" ref-type="fig">Figure&#160;3</xref>).</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>Approach to promoting smoking cessation in patients with PAD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fcvm-10-1154708-g003.jpg"/></fig><sec id="s7a"><label>7.1.</label><title>Pharmacological therapies</title><p>U.S. Food and Drug Administration (FDA)-approved pharmacologic smoking cessation options include nicotine patches, nicotine lozenges, nicotine gum, nicotine inhaler, nicotine nasal spray, as well as medications including bupropion, and varenicline. NRT assists with smoking cessation by providing nicotine instead of cigarettes to suppress the urge to smoke and prevent nicotine withdrawal symptoms. It has been shown that treatment with dual NRT using a patch combined with either gum or lozenges is more effective than a single NRT due to delivering nicotine in both basal and bolus dosing. Though not tested in patients with PAD specifically, NRT has been shown to be safe in patients with established CVD (<xref rid="B60" ref-type="bibr">60</xref>). Bupropion enhances smoking cessation rates compared to placebo. Varenicline has been found to have the greatest success among all options with no reported neuropsychiatric adverse effects compared to placebo (<xref rid="B61" ref-type="bibr">61</xref>).</p></sec><sec id="s7b"><label>7.2.</label><title>E-cigarettes</title><p>E-cigarettes have been introduced in the past two decades as an alternative product to combustible cigarettes and are frequently used in conjunction with or as a replacement for smoking cigarettes. E-cigarettes provide nicotine without burning tobacco and the aerosol has lower amounts of selected potentially harmful compounds (<xref rid="B62" ref-type="bibr">62</xref>). However, the presence of VOCs and flavorings still has the potential for cardiovascular injury. There is limited data regarding the health effects of e-cigarettes including CVD. A recent longitudinal study reported no significant difference in cardiovascular risk between exclusive e-cigarette users and non-users (not using cigarettes or e-cigarettes). However, dual use of e-cigarettes and combustible cigarettes was found to have an increased risk of CVD when compared to non-use. The study suggests that the health benefits of e-cigarettes are only apparent from the complete replacement of cigarettes with e-cigarettes but not from dual use with ongoing smoking (<xref rid="B63" ref-type="bibr">63</xref>). Future longitudinal research is needed to evaluate the long-term health effects of e-cigarettes on PAD outcomes.</p><p>In terms of efficacy for promoting smoking cessation, there remains limited data. A randomized trial compared the 1-year abstinence rate among smokers who received NRT products of their choice either alone or combined vs. smokers who received e-cigarettes. They reported that e-cigarettes were more effective with higher abstinence rates compared to NRT (<xref rid="B64" ref-type="bibr">64</xref>). A non-randomized prospective cohort study evaluated the effectiveness of e-cigarettes on smoking cessation compared to NRT. They reported that smokers who used e-cigarettes alone or in combination with NRT were more likely to report abstinence at 4&#8211;6 weeks follow-up compared to smokers using NRT alone (<xref rid="B65" ref-type="bibr">65</xref>). Importantly, patients in the e-cigarette group had a high rate of continued e-cigarette use. Thus, it will be crucial to understand the longitudinal impact of e-cigarettes on PAD outcomes.</p></sec><sec id="s7c"><label>7.3.</label><title>Behavioral therapy (stepped approach)</title><p>The 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation recommends using both behavioral and pharmacologic therapy. Physicians taking care of patients who smoke should use a four steps plan to help with smoking cessation. First, patients should be asked about their smoking habits and their level of nicotine dependence which has been shown to correlate with their relapse rates after quit attempts. The next step is to give patients clear and personalized advice about the benefits of quitting. It is important that the information provided to patients is tailored toward their specific situation and personal health rather than general advice about the harms of smoking. The third step is to offer patients smoking cessation therapies including behavioral support and pharmacologic treatment. The use of pharmacotherapy is of critical importance and should be offered to every patient who smokes. The next step is to follow up with patients especially within the early period after they quit as the relapse rates are high during this time. Patients require continuous support and encouragement from their healthcare providers to remain smoke-free (<xref rid="B61" ref-type="bibr">61</xref>).</p></sec></sec><sec id="s8"><label>8.</label><title>Regulatory approaches to reduce tobacco use</title><p>Moreover, it is important to develop policies and regulations at a global, government, and organizational level to help with smoking cessation and limit access to tobacco-related products. A joint opinion was issued by the American Heart Association, the World Health Foundation, the American College of Cardiology, and the European Society of Cardiology to decrease and eradicate tobacco use. Suggested strategies include increasing the price and taxation of tobacco products, eliminating advertisements for tobacco products, banning smoking in indoor spaces, having smoke-free workplaces, policies to protect people from secondhand smoke exposure, and characterizing flavors from tobacco products. Two states in the U.S. have banned all flavored tobacco products and it will be important to collect information regarding the effects on both youth and established tobacco product users. Another approach proposed by the FDA is to reduce nicotine content in combustible cigarettes. Additional scientific evidence regarding the specific harmful toxins in tobacco products and how these compounds impact cardiovascular health is crucial to support strong regulatory policies. To address the global tobacco epidemic, we need to advocate for policies proven to limit tobacco use and for the government to take stronger actions to protect public health (<xref rid="B66" ref-type="bibr">66</xref>).</p></sec><sec id="s8a"><label>9.</label><title>Future directions</title><p>The present review emphasizes the significant harmful impact of smoking on patients with PAD. Worse clinical outcomes and the high healthcare costs associated with PAD highlight the importance of smoking cessation for this population. Although many smokers with PAD want to quit, the overall success rates for smoking cessation among this patient population are underwhelming. There is clear underutilization of formal smoking cessation interventions for smokers with PAD. To tackle this issue, we need more effective strategies to help patients quit and also provide ongoing support for continuous abstinence from smoking. More research is needed to assess the long-term effects of smoking cessation interventions including counseling, pharmacotherapy, and the efficacy of e-cigarettes. Also, it is important to advocate for implementing regulatory policies and public health approaches to limit access to tobacco products.</p></sec></body><back><sec id="s9"><title>Author contributions</title><p>LB, AA and NH: contributed to structuring the review, discussing the literature and the knowledge gaps. LB, AA, SHR and NH: wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher's note</title><p>All claims expressed in this article are solely those of theauthors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors andthe reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is notguaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>P</given-names></name><name name-style="western"><surname>Rudan</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>FJI</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Fowkes</surname><given-names>FGR</given-names></name><etal/></person-group><article-title>Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis</article-title>. <source>Lancet Glob Health</source>. (<year>2019</year>) <volume>7</volume>(<issue>8</issue>):<fpage>e1020</fpage>&#8211;<lpage>e1030</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(19)30255-4</pub-id><pub-id pub-id-type="pmid">31303293</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>CW</given-names></name><name name-style="western"><surname>Aday</surname><given-names>AW</given-names></name><name name-style="western"><surname>Almarzooq</surname><given-names>ZI</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2022 update: a report from the American heart association</article-title>. <source>Circulation</source>. (<year>2022</year>) <volume>145</volume>(<issue>8</issue>):<fpage>E153</fpage>&#8211;<lpage>E639</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000001052</pub-id><pub-id pub-id-type="pmid">35078371</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Criqui</surname><given-names>MH</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>K</given-names></name><name name-style="western"><surname>Aboyans</surname><given-names>V</given-names></name><name name-style="western"><surname>Hess</surname><given-names>CN</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American heart association</article-title>. <source>Circulation</source>. (<year>2021</year>) <volume>144</volume>(<issue>9</issue>):<fpage>e171</fpage>&#8211;<lpage>e191</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000001005</pub-id><pub-id pub-id-type="pmid">34315230</pub-id><pub-id pub-id-type="pmcid">PMC9847212</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>KK</given-names></name><name name-style="western"><surname>Jones</surname><given-names>PG</given-names></name><name name-style="western"><surname>Ellerbeck</surname><given-names>EF</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>DM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Underutilization of evidence-based smoking cessation support strategies despite high smoking addiction burden in peripheral artery disease specialty care: insights from the international PORTRAIT registry</article-title>. <source>J Am Heart Assoc</source>. (<year>2018</year>) <volume>7</volume>(<issue>20</issue>):<fpage>e010076</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.118.010076</pub-id><pub-id pub-id-type="pmid">30371269</pub-id><pub-id pub-id-type="pmcid">PMC6474973</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigvant</surname><given-names>B</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>F</given-names></name><name name-style="western"><surname>Wahlberg</surname><given-names>E</given-names></name></person-group>. <article-title>The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2016</year>) <volume>51</volume>(<issue>3</issue>):<fpage>395</fpage>&#8211;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejvs.2015.10.022</pub-id><pub-id pub-id-type="pmid">26777541</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacoub</surname><given-names>PP</given-names></name><name name-style="western"><surname>Abola</surname><given-names>MTB</given-names></name><name name-style="western"><surname>Baumgartner</surname><given-names>I</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><name name-style="western"><surname>Creager</surname><given-names>MA</given-names></name><name name-style="western"><surname>Liau</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the reduction of atherothrombosis for continued health (REACH) registry</article-title>. <source>Atherosclerosis</source>. (<year>2009</year>) <volume>204</volume>(<issue>2</issue>):<fpage>e86</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/J.ATHEROSCLEROSIS.2008.10.023</pub-id><pub-id pub-id-type="pmid">19054514</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornelius</surname><given-names>ME</given-names></name><name name-style="western"><surname>Loretan</surname><given-names>CG</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TW</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>A</given-names></name><name name-style="western"><surname>Homa</surname><given-names>DM</given-names></name></person-group>. <article-title>Tobacco product use among adults&#8212;united States, 2020</article-title>. <source>MMWR Recomm Rep</source>. (<year>2022</year>) <volume>71</volume>(<issue>11</issue>):<fpage>397</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7111a1</pub-id><pub-id pub-id-type="pmcid">PMC8942309</pub-id><pub-id pub-id-type="pmid">35298455</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name></person-group>. <article-title>Burden of peripheral artery disease and its attributable risk factors in 204 countries and territories from 1990 to 2019</article-title>. <source>Front Cardiovasc Med</source>. (<year>2022</year>) <volume>9</volume>:<fpage>868370</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2022.868370</pub-id><pub-id pub-id-type="pmid">35498034</pub-id><pub-id pub-id-type="pmcid">PMC9039520</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>DF</given-names></name><name name-style="western"><surname>Pell</surname><given-names>JP</given-names></name></person-group>. <article-title>Secondhand smoke exposure and risk of incident peripheral arterial disease and mortality: a Scotland-wide retrospective cohort study of 4045 non-smokers with cotinine measurement</article-title>. <source>BMC Public Health</source>. (<year>2018</year>) <volume>18</volume>(<issue>1</issue>):<fpage>348</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-018-5227-x</pub-id><pub-id pub-id-type="pmid">29551089</pub-id><pub-id pub-id-type="pmcid">PMC5858137</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hackler</surname><given-names>EL</given-names></name><name name-style="western"><surname>Hamburg</surname><given-names>NM</given-names></name><name name-style="western"><surname>White Solaru</surname><given-names>KT</given-names></name></person-group>. <article-title>Racial and ethnic disparities in peripheral artery disease</article-title>. <source>Circ Res</source>. (<year>2021</year>) <volume>128</volume>(<issue>12</issue>):<fpage>1913</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.318243</pub-id><pub-id pub-id-type="pmid">34110901</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>D</given-names></name><name name-style="western"><surname>Cain</surname><given-names>LR</given-names></name><name name-style="western"><surname>Blaha</surname><given-names>MJ</given-names></name><name name-style="western"><surname>DeFilippis</surname><given-names>AP</given-names></name><name name-style="western"><surname>Mentz</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Kamimura</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cigarette smoking and subclinical peripheral arterial disease in blacks of the Jackson heart study</article-title>. <source>J Am Heart Assoc</source>. (<year>2019</year>) <volume>8</volume>(<issue>3</issue>):<fpage>e010674</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.118.010674</pub-id><pub-id pub-id-type="pmid">30672360</pub-id><pub-id pub-id-type="pmcid">PMC6405586</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duval</surname><given-names>S</given-names></name><name name-style="western"><surname>Long</surname><given-names>KH</given-names></name><name name-style="western"><surname>Roy</surname><given-names>SS</given-names></name><name name-style="western"><surname>Oldenburg</surname><given-names>NC</given-names></name><name name-style="western"><surname>Harr</surname><given-names>K</given-names></name><name name-style="western"><surname>Fee</surname><given-names>RM</given-names></name><etal/></person-group><article-title>The contribution of tobacco use to high health care utilization and medical costs in peripheral artery disease A state-based cohort analysis</article-title>. <source>J Am Coll Cardiol</source>. (<year>2015</year>) <volume>66</volume>(<issue>14</issue>):<fpage>1566</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.06.1349</pub-id><pub-id pub-id-type="pmid">26429081</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>JC</given-names></name><name name-style="western"><surname>Paul</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Karatas</surname><given-names>TB</given-names></name><name name-style="western"><surname>Kondrasov</surname><given-names>SA</given-names></name><name name-style="western"><surname>McGinigle</surname><given-names>KL</given-names></name><name name-style="western"><surname>Crowner</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Cigarette smoking intensity informs outcomes after open revascularization for peripheral artery disease</article-title>. <source>J Vasc Surg</source>. (<year>2019</year>) <volume>70</volume>(<issue>6</issue>):<fpage>1973</fpage>&#8211;<lpage>1983.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jvs.2019.02.066</pub-id><pub-id pub-id-type="pmid">31176638</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noyes</surname><given-names>AM</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>JD</given-names></name><name name-style="western"><surname>Gosch</surname><given-names>K</given-names></name><name name-style="western"><surname>Smolderen</surname><given-names>K</given-names></name><name name-style="western"><surname>Spertus</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hyder</surname><given-names>O</given-names></name><etal/></person-group><article-title>Association between health status and sociodemographic, clinical and treatment disparities in the patient-centered outcomes related to TReatment practices in peripheral arterial disease: investigating trajectories (PORTRAIT) registry</article-title>. <source>Vasc Med</source>. (<year>2018</year>) <volume>23</volume>(<issue>1</issue>):<fpage>32</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1358863X17747047</pub-id><pub-id pub-id-type="pmid">29338591</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Geng</surname><given-names>K</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name></person-group>. <article-title>Smoking and the pathophysiology of peripheral artery disease</article-title>. <source>Front Cardiovasc Med</source>. (<year>2021</year>) <volume>8</volume>:<fpage>704106</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2021.704106</pub-id><pub-id pub-id-type="pmid">34513948</pub-id><pub-id pub-id-type="pmcid">PMC8429807</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messner</surname><given-names>B</given-names></name><name name-style="western"><surname>Bernhard</surname><given-names>D</given-names></name></person-group>. <article-title>Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2014</year>) <volume>34</volume>(<issue>3</issue>):<fpage>509</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.113.300156</pub-id><pub-id pub-id-type="pmid">24554606</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krishna</surname><given-names>SM</given-names></name><name name-style="western"><surname>Moxon</surname><given-names>JV</given-names></name><name name-style="western"><surname>Golledge</surname><given-names>J</given-names></name></person-group>. <article-title>A review of the pathophysiology and potential biomarkers for peripheral artery disease</article-title>. <source>Int J Mol Sci</source>. (<year>2015</year>) <volume>16</volume>(<issue>5</issue>):<fpage>11294</fpage>&#8211;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.3390/ijms160511294</pub-id><pub-id pub-id-type="pmid">25993296</pub-id><pub-id pub-id-type="pmcid">PMC4463701</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gimbrone</surname><given-names>MA</given-names></name><name name-style="western"><surname>Garc&#237;a-Carde&#241;a</surname><given-names>G</given-names></name></person-group>. <article-title>Endothelial cell dysfunction and the pathobiology of atherosclerosis</article-title>. <source>Circ Res</source>. (<year>2016</year>) <volume>118</volume>(<issue>4</issue>):<fpage>620</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.306301</pub-id><pub-id pub-id-type="pmid">26892962</pub-id><pub-id pub-id-type="pmcid">PMC4762052</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="other"><collab>U.S. Department of Health and Human Services PHSNTP</collab>. <comment><italic toggle="yes">National toxicology program. Tobacco-related exposures. In: Report on Carcinogens</italic>. Fourteenth.; (2016)</comment>.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="other"><collab>Harms of Cigarette Smoking and Health Benefits of Quitting - NCI</collab>. <comment>Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/cessation-fact-sheet" ext-link-type="uri">https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/cessation-fact-sheet</ext-link><comment>(Accessed December 5, 2022)</comment>.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><collab>National Toxicology Program</collab>. <article-title>Tobacco-related exposures: environmental tobacco smoke</article-title>. <source>Report on Carcinogens&#8239;: Carcinogen Profiles / US Dept of Health and Human Services, Public Health Service, National Toxicology Program</source>. (<year>2011</year>) <volume>12</volume>:<fpage>410</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="pmid">21863109</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heiss</surname><given-names>C</given-names></name><name name-style="western"><surname>Amabile</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>AC</given-names></name><name name-style="western"><surname>Real</surname><given-names>WM</given-names></name><name name-style="western"><surname>Schick</surname><given-names>SF</given-names></name><name name-style="western"><surname>Lao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production</article-title>. <source>J Am Coll Cardiol</source>. (<year>2008</year>) <volume>51</volume>(<issue>18</issue>):<fpage>1760</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/J.JACC.2008.01.040</pub-id><pub-id pub-id-type="pmid">18452782</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name></person-group>. <article-title>Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment</article-title>. <source>Prog Cardiovasc Dis</source>. (<year>2003</year>) <volume>46</volume>(<issue>1</issue>):<fpage>91</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/S0033-0620(03)00087-2</pub-id><pub-id pub-id-type="pmid">12920702</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flouris</surname><given-names>AD</given-names></name><name name-style="western"><surname>Vardavas</surname><given-names>CI</given-names></name><name name-style="western"><surname>Metsios</surname><given-names>GS</given-names></name><name name-style="western"><surname>Tsatsakis</surname><given-names>AM</given-names></name><name name-style="western"><surname>Koutedakis</surname><given-names>Y</given-names></name></person-group>. <article-title>Biological evidence for the acute health effects of secondhand smoke exposure</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. (<year>2010</year>) <volume>298</volume>(<issue>1</issue>):<fpage>L3</fpage>&#8211;<lpage>L12</lpage>. <pub-id pub-id-type="doi">10.1152/AJPLUNG.00215.2009</pub-id><pub-id pub-id-type="pmid">19767410</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winniford</surname><given-names>MD</given-names></name><name name-style="western"><surname>Wheelan</surname><given-names>KR</given-names></name><name name-style="western"><surname>Kremers</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ugolini</surname><given-names>V</given-names></name><name name-style="western"><surname>van den Berg</surname><given-names>E</given-names></name><name name-style="western"><surname>Niggemann</surname><given-names>EH</given-names></name><etal/></person-group><article-title>Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone</article-title>. <source>Circulation</source>. (<year>1986</year>) <volume>73</volume>(<issue>4</issue>):<fpage>662</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.73.4.662</pub-id><pub-id pub-id-type="pmid">3948369</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>RMJ</given-names></name><name name-style="western"><surname>Ferrige</surname><given-names>AG</given-names></name><name name-style="western"><surname>Moncada</surname><given-names>S</given-names></name></person-group>. <article-title>Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</article-title>. <source>Nature</source>. (<year>1987</year>) <volume>327</volume>(<issue>6122</issue>):<fpage>524</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/327524A0</pub-id><pub-id pub-id-type="pmid">3495737</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Dong</surname><given-names>F</given-names></name><etal/></person-group><article-title>Nicotine induces endothelial dysfunction and promotes atherosclerosis via GTPCH1</article-title>. <source>J Cell Mol Med</source>. (<year>2018</year>) <volume>22</volume>(<issue>11</issue>):<fpage>5406</fpage>. <pub-id pub-id-type="doi">10.1111/JCMM.13812</pub-id><pub-id pub-id-type="pmid">30091833</pub-id><pub-id pub-id-type="pmcid">PMC6201367</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Qi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis</article-title>. <source>Cell Death Dis</source>. (<year>2018</year>) <volume>9</volume>(<issue>2</issue>):<fpage>171</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-017-0257-3</pub-id><pub-id pub-id-type="pmid">29416034</pub-id><pub-id pub-id-type="pmcid">PMC5833729</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Morata</surname><given-names>I</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>TR</given-names></name><name name-style="western"><surname>Shimbo</surname><given-names>D</given-names></name><name name-style="western"><surname>Navas-Acien</surname><given-names>A</given-names></name></person-group>. <article-title>Electronic cigarette use and blood pressure endpoints: a systematic review</article-title>. <source>Curr Hypertens Rep</source>. (<year>2021</year>) <volume>23</volume>(<issue>1</issue>):<fpage>2</fpage>. <pub-id pub-id-type="doi">10.1007/s11906-020-01119-0</pub-id><pub-id pub-id-type="pmcid">PMC10867863</pub-id><pub-id pub-id-type="pmid">33230755</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeJarnett</surname><given-names>N</given-names></name><name name-style="western"><surname>Conklin</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Riggs</surname><given-names>DW</given-names></name><name name-style="western"><surname>Myers</surname><given-names>JA</given-names></name><name name-style="western"><surname>O'Toole</surname><given-names>TE</given-names></name><name name-style="western"><surname>Hamzeh</surname><given-names>I</given-names></name><etal/></person-group><article-title>Acrolein exposure is associated with increased cardiovascular disease risk</article-title>. <source>J Am Heart Assoc</source>. (<year>2014</year>) <volume>3</volume>(<issue>4</issue>). <pub-id pub-id-type="doi">10.1161/JAHA.114.000934</pub-id><pub-id pub-id-type="pmid">25099132</pub-id><pub-id pub-id-type="pmcid">PMC4310380</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>YS</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>N</given-names></name></person-group>. <article-title>Acrolein induces inflammatory response underlying endothelial dysfunction: a risk factor for atherosclerosis</article-title>. <source>Ann N Y Acad Sci</source>. (<year>2008</year>) <volume>1126</volume>:<fpage>185</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1196/ANNALS.1433.034</pub-id><pub-id pub-id-type="pmid">18448814</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogunwale</surname><given-names>MA</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Ramakrishnam Raju</surname><given-names>MV</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nantz</surname><given-names>MH</given-names></name><name name-style="western"><surname>Conklin</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Aldehyde detection in electronic cigarette aerosols</article-title>. <source>ACS Omega</source>. (<year>2017</year>) <volume>2</volume>(<issue>3</issue>):<fpage>1207</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1021/ACSOMEGA.6B00489/SUPPL_FILE/AO6B00489_SI_001.PDF</pub-id><pub-id pub-id-type="pmid">28393137</pub-id><pub-id pub-id-type="pmcid">PMC5377270</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlachopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Ioakeimidis</surname><given-names>N</given-names></name><name name-style="western"><surname>Abdelrasoul</surname><given-names>M</given-names></name><name name-style="western"><surname>Terentes-Printzios</surname><given-names>D</given-names></name><name name-style="western"><surname>Georgakopoulos</surname><given-names>C</given-names></name><name name-style="western"><surname>Pietri</surname><given-names>P</given-names></name><etal/></person-group><article-title>Electronic cigarette smoking increases aortic stiffness and blood pressure in young smokers</article-title>. <source>J Am Coll Cardiol</source>. (<year>2016</year>) <volume>67</volume>(<issue>23</issue>):<fpage>2802</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/J.JACC.2016.03.569</pub-id><pub-id pub-id-type="pmid">27282901</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carnevale</surname><given-names>R</given-names></name><name name-style="western"><surname>Sciarretta</surname><given-names>S</given-names></name><name name-style="western"><surname>Violi</surname><given-names>F</given-names></name><name name-style="western"><surname>Nocella</surname><given-names>C</given-names></name><name name-style="western"><surname>Loffredo</surname><given-names>L</given-names></name><name name-style="western"><surname>Perri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Acute impact of tobacco vs electronic cigarette smoking on oxidative stress and vascular function</article-title>. <source>Chest</source>. (<year>2016</year>) <volume>150</volume>(<issue>3</issue>):<fpage>606</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/J.CHEST.2016.04.012</pub-id><pub-id pub-id-type="pmid">27108682</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Fraiman</surname><given-names>JB</given-names></name></person-group>. <article-title>Cardiovascular effects of electronic cigarettes</article-title>. <source>Nat Rev Cardiol</source>. (<year>2017</year>) <volume>14</volume>(<issue>8</issue>):<fpage>447</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/NRCARDIO.2017.36</pub-id><pub-id pub-id-type="pmid">28332500</pub-id><pub-id pub-id-type="pmcid">PMC5519136</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammadi</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>DD</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A</given-names></name><name name-style="western"><surname>Derakhshandeh</surname><given-names>R</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P</given-names></name><etal/></person-group><article-title>Chronic e-cigarette use impairs endothelial function on the physiological and cellular levels</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2022</year>) <volume>42</volume>(<issue>11</issue>):<fpage>1333</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.121.317749</pub-id><pub-id pub-id-type="pmid">36288290</pub-id><pub-id pub-id-type="pmcid">PMC9625085</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fetterman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Keith</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Palmisano</surname><given-names>JN</given-names></name><name name-style="western"><surname>McGlasson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Weisbrod</surname><given-names>RM</given-names></name><name name-style="western"><surname>Majid</surname><given-names>S</given-names></name><etal/></person-group><article-title>Alterations in vascular function associated with the use of combustible and electronic cigarettes</article-title>. <source>J Am Heart Assoc</source>. (<year>2020</year>) <volume>9</volume>(<issue>9</issue>):<fpage>e014570</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.119.014570</pub-id><pub-id pub-id-type="pmid">32345096</pub-id><pub-id pub-id-type="pmcid">PMC7428567</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majid</surname><given-names>S</given-names></name><name name-style="western"><surname>Weisbrod</surname><given-names>RM</given-names></name><name name-style="western"><surname>Fetterman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Keith</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>SHM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pod-based e-liquids impair human vascular endothelial cell function</article-title>. <source>PLoS One</source>. (<year>2023</year>) <volume>18</volume>(<issue>1</issue>):<fpage>e0280674</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0280674</pub-id><pub-id pub-id-type="pmid">36701344</pub-id><pub-id pub-id-type="pmcid">PMC9879485</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fetterman</surname><given-names>JL</given-names></name><name name-style="western"><surname>Weisbrod</surname><given-names>RM</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B</given-names></name><name name-style="western"><surname>Bastin</surname><given-names>R</given-names></name><name name-style="western"><surname>Tuttle</surname><given-names>ST</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M</given-names></name><etal/></person-group><article-title>Flavorings in tobacco products induce endothelial cell dysfunction</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2018</year>) <volume>38</volume>(<issue>7</issue>):<fpage>1607</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311156</pub-id><pub-id pub-id-type="pmid">29903732</pub-id><pub-id pub-id-type="pmcid">PMC6023725</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>WH</given-names></name><name name-style="western"><surname>Ong</surname><given-names>SG</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><name name-style="western"><surname>Bae</surname><given-names>HR</given-names></name><name name-style="western"><surname>Baker</surname><given-names>N</given-names></name><etal/></person-group><article-title>Modeling cardiovascular risks of e-cigarettes with human-induced pluripotent stem cell&#8211;derived endothelial cells</article-title>. <source>J Am Coll Cardiol</source>. (<year>2019</year>) <volume>73</volume>(<issue>21</issue>):<fpage>2722</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2019.03.476</pub-id><pub-id pub-id-type="pmid">31146818</pub-id><pub-id pub-id-type="pmcid">PMC6637948</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name><name name-style="western"><surname>Shipley</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rose</surname><given-names>G</given-names></name></person-group>. <article-title>Intermittent claudication, heart disease risk factors, and mortality. The whitehall study</article-title>. <source>Circulation</source>. (<year>1990</year>) <volume>82</volume>(<issue>6</issue>):<fpage>1925</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.82.6.1925</pub-id><pub-id pub-id-type="pmid">2242518</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duncan</surname><given-names>MS</given-names></name><name name-style="western"><surname>Freiberg</surname><given-names>MS</given-names></name><name name-style="western"><surname>Greevy</surname><given-names>RA</given-names></name><name name-style="western"><surname>Kundu</surname><given-names>S</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>RS</given-names></name><name name-style="western"><surname>Tindle</surname><given-names>HA</given-names></name></person-group>. <article-title>Association of smoking cessation with subsequent risk of cardiovascular disease</article-title>. <source>JAMA</source>. (<year>2019</year>) <volume>322</volume>(<issue>7</issue>):<fpage>642</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1001/JAMA.2019.10298</pub-id><pub-id pub-id-type="pmid">31429895</pub-id><pub-id pub-id-type="pmcid">PMC6704757</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannel</surname><given-names>W</given-names></name><name name-style="western"><surname>Shurtleff</surname><given-names>D</given-names></name></person-group>. <article-title>The Framingham study. Cigarettes and the development of intermittent claudication</article-title>. <source>Geriatrics</source>. (<year>1973</year>) <volume>28</volume>(<issue>2</issue>):<fpage>61</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">4683662</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughson</surname><given-names>WG</given-names></name><name name-style="western"><surname>Mann</surname><given-names>JI</given-names></name><name name-style="western"><surname>Garrod</surname><given-names>A</given-names></name></person-group>. <article-title>Intermittent claudication: prevalence and risk factors</article-title>. <source>Br Med J</source>. (<year>1978</year>) <volume>1</volume>(<issue>6124</issue>):<fpage>1379</fpage>. <pub-id pub-id-type="doi">10.1136/BMJ.1.6124.1379</pub-id><pub-id pub-id-type="pmid">647301</pub-id><pub-id pub-id-type="pmcid">PMC1604804</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quick</surname><given-names>CRG</given-names></name><name name-style="western"><surname>Cotton</surname><given-names>LT</given-names></name></person-group>. <article-title>The measured effect of stopping smoking on intermittent claudication</article-title>. <source>Br J Surg</source>. (<year>1982</year>) <volume>69</volume>(<issue>Suppl(6 S)</issue>):<fpage>S24</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/BJS.1800691309</pub-id><pub-id pub-id-type="pmid">7082968</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willigendael</surname><given-names>EM</given-names></name><name name-style="western"><surname>Teijink</surname><given-names>JAW</given-names></name><name name-style="western"><surname>Bartelink</surname><given-names>ML</given-names></name><name name-style="western"><surname>Peters</surname><given-names>RJG</given-names></name><name name-style="western"><surname>B&#252;ller</surname><given-names>HR</given-names></name><name name-style="western"><surname>Prins</surname><given-names>MH</given-names></name></person-group>. <article-title>Smoking and the patency of lower extremity bypass grafts: a meta-analysis</article-title>. <source>J Vasc Surg</source>. (<year>2005</year>) <volume>42</volume>(<issue>1</issue>):<fpage>67</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jvs.2005.03.024</pub-id><pub-id pub-id-type="pmid">16012454</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>DW</given-names></name><name name-style="western"><surname>Goodney</surname><given-names>PP</given-names></name><name name-style="western"><surname>Eldrup-Jorgensen</surname><given-names>J</given-names></name><name name-style="western"><surname>Schermerhorn</surname><given-names>ML</given-names></name><name name-style="western"><surname>Siracuse</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Active smoking in claudicants undergoing lower extremity bypass predicts decreased graft patency and worse overall survival</article-title>. <source>J Vasc Surg</source>. (<year>2018</year>) <volume>68</volume>(<issue>3</issue>):<fpage>796</fpage>&#8211;<lpage>806.e1</lpage>. <pub-id pub-id-type="doi">10.1016/J.JVS.2017.12.044</pub-id><pub-id pub-id-type="pmid">29523437</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farber</surname><given-names>A</given-names></name><name name-style="western"><surname>Menard</surname><given-names>MT</given-names></name><name name-style="western"><surname>Conte</surname><given-names>MS</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>JA</given-names></name><name name-style="western"><surname>Powell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Choudhry</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Surgery or endovascular therapy for chronic limb-threatening ischemia</article-title>. <source>N Engl J Med</source>. (<year>2022</year>) <volume>387</volume>(<issue>25</issue>):<fpage>2305</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMOA2207899</pub-id><pub-id pub-id-type="pmid">36342173</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>GD</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>DL</given-names></name><name name-style="western"><surname>Pevec</surname><given-names>WC</given-names></name><name name-style="western"><surname>Amsterdam</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease</article-title>. <source>J Vasc Surg</source>. (<year>2014</year>) <volume>60</volume>(<issue>6</issue>):<fpage>1565</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/J.JVS.2014.08.064</pub-id><pub-id pub-id-type="pmid">25282696</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>KM</given-names></name><name name-style="western"><surname>Althouse</surname><given-names>AD</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J</given-names></name><name name-style="western"><surname>Arya</surname><given-names>S</given-names></name><name name-style="western"><surname>Goodney</surname><given-names>PP</given-names></name><name name-style="western"><surname>Shireman</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Association of smoking with postprocedural complications following open and endovascular interventions for intermittent claudication</article-title>. <source>JAMA Cardiol</source>. (<year>2022</year>) <volume>7</volume>(<issue>1</issue>):<fpage>45</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1001/JAMACARDIO.2021.3979</pub-id><pub-id pub-id-type="pmid">34613348</pub-id><pub-id pub-id-type="pmcid">PMC8495608</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creager</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hamburg</surname><given-names>NM</given-names></name></person-group>. <article-title>Smoking cessation improves outcomes in patients with peripheral artery disease</article-title>. <source>JAMA Cardiol</source>. (<year>2022</year>) <volume>7</volume>(<issue>1</issue>):<fpage>15</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1001/JAMACARDIO.2021.3987</pub-id><pub-id pub-id-type="pmid">34613351</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mozaffarian</surname><given-names>D</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Go</surname><given-names>AS</given-names></name><name name-style="western"><surname>Arnett</surname><given-names>DK</given-names></name><name name-style="western"><surname>Blaha</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cushman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2015 update&#8239;: a report from the American heart association</article-title>. <source>Circulation</source>. (<year>2015</year>) <volume>131</volume>(<issue>4</issue>):<fpage>e29</fpage>&#8211;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000152</pub-id><pub-id pub-id-type="pmid">25520374</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahoney</surname><given-names>EM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Keo</surname><given-names>HH</given-names></name><name name-style="western"><surname>Duval</surname><given-names>S</given-names></name><name name-style="western"><surname>Smolderen</surname><given-names>KG</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. (<year>2010</year>) <volume>3</volume>(<issue>6</issue>):<fpage>642</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.109.930735</pub-id><pub-id pub-id-type="pmid">20940249</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerhard-Herman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Gornik</surname><given-names>HL</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>C</given-names></name><name name-style="western"><surname>Barshes</surname><given-names>NR</given-names></name><name name-style="western"><surname>Corriere</surname><given-names>MA</given-names></name><name name-style="western"><surname>Drachman</surname><given-names>DE</given-names></name><etal/></person-group><article-title>2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines</article-title>. <source>Circulation</source>. (<year>2017</year>) <volume>135</volume>(<issue>12</issue>):<fpage>e726</fpage>&#8211;<lpage>e779</lpage>. <pub-id pub-id-type="doi">10.1161/CIR.0000000000000471</pub-id><pub-id pub-id-type="pmid">27840333</pub-id><pub-id pub-id-type="pmcid">PMC5477786</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babb</surname><given-names>S</given-names></name><name name-style="western"><surname>Malarcher</surname><given-names>A</given-names></name><name name-style="western"><surname>Schauer</surname><given-names>G</given-names></name><name name-style="western"><surname>Asman</surname><given-names>K</given-names></name><name name-style="western"><surname>Jamal</surname><given-names>A</given-names></name></person-group>. <article-title>Quitting smoking among adults&#8212;united States, 2000&#8211;2015</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2017</year>) <volume>65</volume>(<issue>52</issue>):<fpage>1457</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6552a1</pub-id><pub-id pub-id-type="pmid">28056007</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Creamer</surname><given-names>MR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TW</given-names></name><name name-style="western"><surname>Babb</surname><given-names>S</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>KA</given-names></name><name name-style="western"><surname>Day</surname><given-names>H</given-names></name><name name-style="western"><surname>Willis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tobacco product use and cessation indicators among adults&#8212;United States, 2018</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. (<year>2019</year>) <volume>68</volume>(<issue>45</issue>):<fpage>1013</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6845a2</pub-id><pub-id pub-id-type="pmid">31725711</pub-id><pub-id pub-id-type="pmcid">PMC6855510</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennrikus</surname><given-names>D</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lando</surname><given-names>HA</given-names></name><name name-style="western"><surname>Duval</surname><given-names>S</given-names></name><name name-style="western"><surname>Ukestad</surname><given-names>L</given-names></name><name name-style="western"><surname>Kodl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial</article-title>. <source>J Am Coll Cardiol</source>. (<year>2010</year>) <volume>56</volume>(<issue>25</issue>):<fpage>2105</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2010.07.031</pub-id><pub-id pub-id-type="pmid">21144971</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalbaugh</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Luckett</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Fine</surname><given-names>J</given-names></name><name name-style="western"><surname>Brothers</surname><given-names>TE</given-names></name><name name-style="western"><surname>Farber</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The impact of current smoking on outcomes after infrainguinal bypass for claudication</article-title>. <source>J Vasc Surg</source>. (<year>2018</year>) <volume>68</volume>(<issue>2</issue>):<fpage>495</fpage>&#8211;<lpage>502.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.jvs.2017.10.091</pub-id><pub-id pub-id-type="pmid">29506947</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodney</surname><given-names>PP</given-names></name><name name-style="western"><surname>Spangler</surname><given-names>EL</given-names></name><name name-style="western"><surname>Newhall</surname><given-names>K</given-names></name><name name-style="western"><surname>Brooke</surname><given-names>BS</given-names></name><name name-style="western"><surname>Schanzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Tan</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) trial</article-title>. <source>J Vasc Surg</source>. (<year>2017</year>) <volume>65</volume>(<issue>4</issue>):<fpage>1152</fpage>&#8211;<lpage>1160.e2</lpage>. <pub-id pub-id-type="doi">10.1016/j.jvs.2016.10.121</pub-id><pub-id pub-id-type="pmid">28190719</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Pipe</surname><given-names>A</given-names></name><name name-style="western"><surname>West</surname><given-names>R</given-names></name><name name-style="western"><surname>Hays</surname><given-names>JT</given-names></name><name name-style="western"><surname>Tonstad</surname><given-names>S</given-names></name><name name-style="western"><surname>McRae</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers a randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. (<year>2018</year>) <volume>178</volume>(<issue>5</issue>):<fpage>622</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2018.0397</pub-id><pub-id pub-id-type="pmid">29630702</pub-id><pub-id pub-id-type="pmcid">PMC6145797</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barua</surname><given-names>RS</given-names></name><name name-style="western"><surname>Rigotti</surname><given-names>NA</given-names></name><name name-style="western"><surname>Benowitz</surname><given-names>NL</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>KM</given-names></name><name name-style="western"><surname>Jazayeri</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morris</surname><given-names>PB</given-names></name><etal/></person-group><article-title>2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American college of cardiology task force on clinical expert consensus documents</article-title>. <source>J Am Coll Cardiol</source>. (<year>2018</year>) <volume>72</volume>(<issue>25</issue>):<fpage>3332</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2018.10.027</pub-id><pub-id pub-id-type="pmid">30527452</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>PB</given-names></name><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name><name name-style="western"><surname>Jahangir</surname><given-names>E</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>DN</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Bahrami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the prevention of cardiovascular disease section leadership council and early career councils of the American college of cardiology</article-title>. <source>J Am Coll Cardiol</source>. (<year>2015</year>) <volume>66</volume>(<issue>12</issue>):<fpage>1378</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.07.037</pub-id><pub-id pub-id-type="pmid">26383726</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlowitz</surname><given-names>JB</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W</given-names></name><name name-style="western"><surname>Harlow</surname><given-names>AF</given-names></name><name name-style="western"><surname>Hamburg</surname><given-names>NM</given-names></name><name name-style="western"><surname>Blaha</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>A</given-names></name><etal/></person-group><article-title>E-cigarette use and risk of cardiovascular disease: a longitudinal analysis of the PATH study (2013&#8211;2019)</article-title>. <source>Circulation</source>. (<year>2022</year>) <volume>145</volume>(<issue>20</issue>):<fpage>1557</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.057369</pub-id><pub-id pub-id-type="pmid">35514292</pub-id><pub-id pub-id-type="pmcid">PMC9362726</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajek</surname><given-names>P</given-names></name><name name-style="western"><surname>Phillips-Waller</surname><given-names>A</given-names></name><name name-style="western"><surname>Przulj</surname><given-names>D</given-names></name><name name-style="western"><surname>Pesola</surname><given-names>F</given-names></name><name name-style="western"><surname>Myers Smith</surname><given-names>K</given-names></name><name name-style="western"><surname>Bisal</surname><given-names>N</given-names></name><etal/></person-group><article-title>A randomized trial of e-cigarettes versus nicotine-replacement therapy</article-title>. <source>N Engl J Med</source>. (<year>2019</year>) <volume>380</volume>(<issue>7</issue>):<fpage>629</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa1808779</pub-id><pub-id pub-id-type="pmid">30699054</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>S</given-names></name><name name-style="western"><surname>Dawkins</surname><given-names>L</given-names></name><name name-style="western"><surname>Doshi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>J</given-names></name></person-group>. <article-title>Effects of e-cigarettes versus nicotine replacement therapy on short-term smoking abstinence when delivered at a community pharmacy</article-title>. <source>Addict Behav Rep</source>. (<year>2019</year>) <volume>10</volume>:<fpage>100202</fpage>. <pub-id pub-id-type="doi">10.1016/j.abrep.2019.100202</pub-id><pub-id pub-id-type="pmid">31338412</pub-id><pub-id pub-id-type="pmcid">PMC6626064</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willett</surname><given-names>J</given-names></name><name name-style="western"><surname>Achenbach</surname><given-names>S</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Poppas</surname><given-names>A</given-names></name><name name-style="western"><surname>Elkind</surname><given-names>MSV</given-names></name></person-group>. <article-title>The tobacco endgame: eradicating a worsening epidemic a joint opinion from the American heart association, world heart federation, American college of cardiology, and the European society of cardiology</article-title>. <source>J Am Coll Cardiol</source>. (<year>2021</year>) <volume>78</volume>(<issue>1</issue>):<fpage>77</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2021.04.005</pub-id><pub-id pub-id-type="pmid">34052093</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>